CClinicalTrials.gg
CompletedNCT05352568Updated Aug 22, 2023

Is Cognitive Training an Option?

An interventional study of Cognitive Training in Schizophrenia, Schizoaffective and Cognition, sponsored by Alliant International University. Completed at 1 site in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2023-08-22.

Sponsored by Alliant International University · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Ages
18 Years to 65 Years
Sex
All
01

Study summary

The purpose of the study is to evaluate the feasibility of implementing cognitive training with 40 patients living with schizophrenia and schizoaffective disorder. The study aims to explore if cognitive training as an intervention can improve cognition, symptomology, social cognition, and psychosocial function which has been determined through literature to be impacted within this population. The results of this study will help shed light on utilizing additional resources to aid in decreasing relapse and continued hospitalizations.

Read the detailed description

After being selected for this study based on a screening survey, participants will be asked to fill out a demographic questionnaire, the Multidimensional Schizotypy Scale - Brief Version (MSS-B), the Montreal Cognitive Assessment (MoCA), the Davos Assessment of Cognitive Biases Scale (DACOBS), and the Illness Management and Recovery Scale - Consumer Self-Rating, IMRS. The measurements evaluate different aspects of severe mental illness which are often challenges. This will take approximately: the screener questionnaire (2-3 minutes), demographic questionnaire (3-5 minutes), MSS-B (38 questions: 10-15 minutes), MoCA (10-15 minutes), DACOBS (42 questions: 15-20 minutes), and IMS (15 questions: 5 to 15 minutes)- Total Maximum Time is 63 minutes. After all, measurements are completed, the participants will be introduced to the BrainHQ program the following week. The participants will begin the selected cognitive training module 3 times a week (Mon, Wed, and Fri), 60 minutes per session for a total of 180 minutes per week. The participants will have a total of 24 sessions over the course of 8 weeks, for a total of 1,440 minutes of cognitive training over the course of this feasibility study. A process questionnaire on the acceptability/ feasibility of the cognitive training program will be administered after the first session, then the middle progress point (4th week), and at the end of the program (8th week) (2-3 minutes). Upon completion of the cognitive training, the participants will retake each measurement (MSS-B, MoCA, DACOBS, and IMRS)-Total Maximum Time is 55 minutes. There is minimal to no risk in this study. Participants will continue their prescribed treatment plan with the addition of the cognitive training which is computerized and takes the form of simulated games with an attended purpose. Participants will continue to be monitored by their providers and staff will continue to evaluate participants for changes in baseline behavior on a daily basis during the course of the study. The plan analysis for this study will be a MANOVA and Correlations. Confidentiality of research records and data will be protected in accordance with the Alliant International University Institutional Review Boards policies, and procedures.

02

Conditions studied

  • Schizophrenia
  • Schizoaffective
  • Cognition

Browse trials for

Keywords

  • Schizophrenia
  • Schizoaffective
  • Cognition
  • Social Cognition
  • Psychosocial Function
03

In context

Schizophrenia

3,471 studies on the registry are indexed under Schizophrenia; 472 are open to participants now.

This study's enrollment of 30 is below the median of 70 across 2,872 interventional studies indexed under Schizophrenia.

Browse Schizophrenia studies →

Lead sponsor

Alliant International University is the lead sponsor of 3 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • 18 years and older
  • A diagnosis of schizophrenia or schizoaffective disorder
  • All genders
  • All sexual orientations
  • All class/ social-economic status
  • All ethnicities

Exclusion criteria

Exclusion Criteria:

  • An inability to understand the consent process and/or provide assent
  • Inability to understand the assent form/process
  • Not being a fluent English speaker
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (actual)

Study arms

  • Experimental
    Cognitive Group

    Computer Cognitive-Based Training

    Behavioral: Cognitive Training

Interventions

  • BehavioralCognitive Training

    Computer-Based Cognitive Training from BrainHQ (Posit Science)

06

What researchers measure

Primary outcomes

  1. Montreal Cognitive Assessment (MoCA)

    A quick screening tool for mild cognitive impairments (MCI) and early Alzheimer's dementia.

    Time frame: 10-15 minutes

Secondary outcomes

  1. Davos Assessment of Cognitive Biases Scale (DACOBS)

    A self-report measure of cognitive biases and cognitive limitations that contributes to psychosis.

    Time frame: 15-20 minutes

  2. Illness Management and Recovery Scale - Consumer Self-Rating, IMRS

    A psychosocial functioning assessment for individuals with schizophrenia.

    Time frame: 5-15 minutes

  3. Multidimensional Schizotypy Scale - Brief Version (MSS-B)

    A symptomology assessment with a subscale consisting of positive, negative, and disorganized dimensions of schizotypy.

    Time frame: 10-15 minutes

07

Study locations

1 site
  • View Heights Convalescent Hospital
    Los Angeles, California 90061, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Aug 22, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05352568
Lead sponsor
Alliant International University
Responsible party
Andre Pierre Longino, M.A. (Researcher, Alliant International University) — Principal investigator
First posted
Apr 29, 2022
Start date
May 2, 2022
Primary completion
Mar 1, 2023
Completion
Jun 30, 2023
Last update
Aug 22, 2023

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion